Scarica l'app Stockscreener
44.50
0.80%
-0.36
Dopo l'orario di chiusura:
44.50
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance
uniQure Submits BLA and MAA for AMT-130 Gene Therapy in Huntington's Disease - BioPharm International
QURE Submits Application for Gene Therapy for Huntington's Disease - theglobeandmail.com
QURE Reinstated by William Blair -- Rating Set to Outperform - GuruFocus
Why is Uniqure NV stock gaining today? - Investing.com
uniQure seeks FDA accelerated nod for gene therapy (QURE) - Seeking Alpha
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says - Benzinga
uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
Why is Uniqure NV stock gaining today? By Investing.com - Investing.com Canada
QURE Looks 505.1% Overvalued on GF Value™ - GuruFocus
UniQure Submits BLA for AMT-130 in Huntington's Disease - marketscreener.com
uniQure submits BLA to FDA and MAA to MHRA for AMT-130 in Huntington’s disease - TradingView
uniQure Announces Submission of Biologics License - GlobeNewswire
Uniqure (QURE) Financials FY2025: Revenue $16.1M, Net Loss $199.0M | Income Statement & Balance Sheet - Stock Titan
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Yahoo Finance
Price to sales forward of uniQure N.V. – NASDAQ:QURE - TradingView
RTW INVESTMENTS, LP Buys uniQure NV (QURE) -- Shares Look 531% O - GuruFocus
uniQure N.V. - Reuters
Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE - MarketBeat
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure (QURE) Advances 3.31% as Gene Therapy Optimism ReturnsDividend Growth Stocks - Vinanet
Responsive Playbooks and the QURE Inflection - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71 - Moomoo
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
Uniqure NV (QURE) Stock News Today - TradingKey
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: Exploring A 53.35% Potential Upside In Gene Therapy - DirectorsTalk Interviews
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
QURE|Uniqure NV|Price:44.206|Chg%:-0.034 - TradingKey
Weekly Recap: AMT-130 readout and Wells Fargo raises QURE target to $75 - TradingView
Militia Capital Management LLC Invests $1.54 Million in uniQure N.V. $QURE - MarketBeat
uniQure N.V. (QURE) Stock Analysis: Assessing Upside Potential and Analyst Confidence in Biotech Innovator - DirectorsTalk Interviews
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course (NASDAQ:QURE) - Seeking Alpha
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - TradingView
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - Moomoo
Uniqure NV earnings missed by $0.38, revenue topped estimates - Investing.com Nigeria
uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary - TradingView
UniQure: Q2 Earnings Snapshot - 10tv.com
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update - GlobeNewswire
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure earnings in focus as AMT-130 gene therapy BLA looms By Investing.com - Investing.com Australia
uniQure earnings in focus as AMT-130 gene therapy BLA looms - Investing.com
Uniqure NV (QURE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Uniqure NV (QURE) Income Statement - TradingKey
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Uniqure NV (QURE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kalehua Capital Management LLC Makes New Investment in uniQure N.V. $QURE - MarketBeat
Orbimed Advisors LLC Has $34.93 Million Holdings in uniQure N.V. $QURE - MarketBeat
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):